New hope for Tough-to-Treat ovarian cancer
Disease control
Completed
This study tested a new drug called SL-172154, given alongside one of two standard chemotherapy drugs, in people with ovarian cancer that had stopped responding to platinum-based treatments. The main goals were to find a safe dose and see if the combinations showed early signs of…
Phase: PHASE1 • Sponsor: Shattuck Labs, Inc. • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC